The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
Treatment intensification in people with type 2 diabetes following failure of basal insulin commonly involves the addition of a rapid-acting insulin analogue (basal plus one or more prandial doses; multiple daily injections) or by a switch to premixed insulin. Insulin degludec/insulin aspart (IDegAs...
Main Authors: | Sarah J. Glastras, Neale Cohen, Thomas Dover, Gary Kilov, Richard J. MacIsaac, Margaret McGill, Greg R. Fulcher |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/4/1091 |
Similar Items
-
Safety of Insulin Degludec/Insulin Aspart in Patients with Diabetes Mellitus over a Period of 1 Year during Routine Clinical Care in India: SMART (Study of Management of Diabetes with Ryzodeg™ Treatment)
by: Jothydev Kesavadev, et al.
Published: (2021-12-01) -
Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients
by: Tarık Kırkgöz, et al.
Published: (2022-03-01) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01) -
Practical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia
by: Siew Pheng Chan, et al.
Published: (2023-05-01) -
Insulin degludec aspart: One-year real world experience
by: Sanjay Kalra, et al.
Published: (2016-01-01)